AAPG Ascentage Pharma Group Internat - Fundamental Analysis

BEARISH

AAPG Stock | Fundamental Analysis & Investment Insights

NASDAQ • Healthcare • Biotechnology

Current Price Live

$23.82

Analyst Target

$45.71

+91.9% Upside

52W High

$48.45

52W Low

$17.55

Overview AI Snowflake Price Valuation Profitability Growth Health Peers Insiders

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Feb 14, 2026

Market cap

$2.23B

P/E

N/A

ROE

-159.6%

Profit margin

-296.8%

Debt/Equity

2.54

Dividend yield

N/A

AI Analysis

Confidence Score

85%

Analysis Accuracy

AAPG's Piotroski F-Score of 4/9 indicates weak financial health, falling into the 'Weak' range for biotech firms, with no Altman Z-Score available to assess bankruptcy risk. The company exhibits severe profitability issues, with a negative profit margin of -296.77% and ROE of -159.65%, alongside a 71.6% YoY revenue decline. Despite a high gross margin of 90.87%, this is likely due to low R&D and operating expenses relative to revenue, not sustainable profitability. The stock trades at a premium valuation (Price/Book: 84.82) with no earnings or cash flow support, and technical indicators show strong bearish momentum. Analysts have a target price of $45.71, but with no consensus recommendation and a 6-month return of -47.1%, sentiment remains fragile.

Key Strengths

High gross margin of 90.87% suggests strong product-level pricing power or low cost of goods sold

Positive insider sentiment (40/100) indicates some confidence from management

Trading above 52-week low ($17.55) and near 50-day average (implied) suggests short-term support

Sector-wide average revenue growth of 62.30% indicates strong industry tailwinds

Forward P/E of -49.55 implies market pricing in future earnings recovery, not current profitability

Key Risks

Piotroski F-Score of 4/9 signals weak financial health and deteriorating operational efficiency

Negative profit margin (-296.77%) and ROE (-159.65%) indicate severe unprofitability

71.6% YoY revenue decline suggests core business contraction or product failure

Debt/Equity ratio of 2.54 is high for a biotech, especially with negative ROIC and no cash flow

No analyst consensus or target mean, and 6-month price drop of 47.1% reflects deteriorating market confidence

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall

Weak

Value

Future

Past

Health

Dividend

AI Verdict

Weak

Key drivers: Negative profitability and revenue decline, Low Piotroski F-Score, High valuation without earnings support, Bearish technical trend, No analyst consensus

Confidence

85%

Value

20/100

P/E and PEG are not meaningful due to negative earnings; Price/Book is inflated, indicating premium valuation without fundamental support.

Positives

High gross margin may signal product strength
Forward P/E suggests market expects future earnings recovery

Watchpoints

No Graham Number or intrinsic value available
Price/Book of 84.82 is extremely high
No operating cash flow or free cash flow data
Negative earnings and revenue growth

Future

30/100

Growth expectations are priced in, but current performance shows contraction, creating a disconnect between market optimism and operational reality.

Positives

Forward P/E of -49.55 implies high growth expectations
Analysts have a target price of $45.71, suggesting upside potential

Watchpoints

71.6% YoY revenue decline contradicts growth narrative
No Q/Q or earnings growth data available
Negative ROIC and no cash flow metrics

Past

25/100

Historical returns are strong, but recent performance is bearish, and earnings have not met expectations.

Positives

5-year return of +37.0% shows historical outperformance
1-year return of +38.0% indicates strong momentum in prior period

Watchpoints

6-month return of -47.1% shows sharp reversal
1-month return of -15.9% indicates recent deterioration
No earnings beat history (0/2 quarters)

Health

20/100

Financial health is weak; Piotroski score is low, and profitability is severely negative, indicating high risk.

Positives

Current ratio of 1.54 and quick ratio of 1.40 suggest short-term liquidity

Watchpoints

Piotroski F-Score of 4/9 is below threshold for financial stability
No Altman Z-Score available, but debt/equity of 2.54 is high
Negative ROE and ROA indicate poor capital efficiency
No cash flow or debt figures available, but negative profitability is a red flag

Dividend

0/100

No dividend is paid, and the company is not in a position to initiate one given its losses and negative cash flow.

Positives

No standout positives identified.

Watchpoints

Dividend yield and payout ratio are 0
No dividend history or payment

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price

$23.82

Analyst Target

$45.71

Upside/Downside

+91.9%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for AAPG and closest competitors.

Updated 2026-02-13

Company	5Y	3Y	1Y	6M	1M	1W
AAPG Ascentage Pharma Group Internat Primary	+37.0%	+37.0%	+38.0%	-47.1%	-15.9%	-2.9%
BHC Bausch Health Companies Inc. Peer	-78.1%	-29.4%	-24.3%	-12.7%	-17.7%	-15.3%
ATEC Alphatec Holdings, Inc. Peer	+4.7%	+20.4%	+33.9%	+44.4%	-24.8%	-11.9%
ADUS Addus HomeCare Corporation Peer	-6.3%	+8.5%	-1.5%	-1.1%	+3.0%	+7.5%
AORT Artivion, Inc. Peer	+72.4%	+236.1%	+40.5%	+37.0%	-8.2%	-0.8%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

N/A

-49.55

N/A

84.82

5.7

21.13

-7.9

$2.23B

Profitability

Profit margins and return metrics

Profit Margin -296.77%

Operating Margin -237.05%

Gross Margin 90.87%

ROE -159.65%

ROA -22.77%

Growth

Revenue and earnings growth rates

Revenue Growth -71.6%

Earnings Growth N/A

Q/Q Revenue Growth N/A

Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity

2.54

High debt

Current Ratio

1.54

Good

Quick Ratio

1.4

Good

Cash/Share

$4.83

Quarterly Earnings History

EPS performance vs analyst estimates

2026-03-26

$N/A

2025-08-07

$N/A

Healthcare Sector Comparison

Comparing AAPG against 146 companies in the Healthcare sector (10 bullish, 60 neutral, 76 bearish)

Return on Equity (ROE)

-159.65%

This Stock

-56.84%

Sector Avg

+180.9% (Excellent)

Profit Margin

-296.77%

This Stock

-20.8%

Sector Avg

+1327.0% (Superior)

Debt to Equity

2.54

This Stock

2.68

Sector Avg

-5.3% (Lower)

Revenue Growth

-71.6%

This Stock

61.93%

Sector Avg

-215.6% (Slower)

Current Ratio

1.54

This Stock

3.47

Sector Avg

-55.6% (Weaker)

Similar Companies

Peer comparison within the same industry

Company	AI Rating	Market Cap	P/E	ROE	Profit Margin	Price
AAPG Ascentage Pharma Group Internat	BEARISH	$2.23B	-	-159.6%	-296.8%	$23.82
BHC Bausch Health Companies Inc.	BEARISH	$2.19B	6.79	563.2%	3.6%	$5.91
ATEC Alphatec Holdings, Inc.	BEARISH	$2.32B	-	-540.4%	-21.3%	$15.62
ADUS Addus HomeCare Corporation	NEUTRAL	$2.1B	24.11	8.6%	6.4%	$113.8
AORT Artivion, Inc.	BEARISH	$2.04B	-	-2.5%	-2.2%	$43.02

Wall Street Analysts

Professional analyst ratings and price targets

Consensus

NONE

7 analysts

Oppenheimer

2025-12-04

init

Outperform

Truist Securities

2025-11-24

init

Buy

BTIG

2025-11-10

init

Buy

Piper Sandler

2025-11-05

init

Overweight

Past News Coverage

Recent headlines mentioning AAPG from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V1 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends